# US 2016/0354404 A1 · Compositions and Methods for Inhibition of PCSK9 Genes

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0354404 A1
- Document ID: US20160354404A1
- Status: Published application
- Kind: A1
- Application number: 15/072,016
- Filed: 2016-03-16
- Published: 2016-12-08
- Earliest claimed: 2010-10-29
- Assignees: Alnylam Pharmaceuticals, Inc.
- Applicants: Alnylam Pharmaceuticals, Inc.
- Inventors: Gregory Hinkle; Maria Frank-Kamenetsky; Kevin Fitzgerald
- Web page: https://patentgrep.com/patent/US20160354404A1

## CPC

- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61P 3/06: Antihyperlipidemics
- C12N 15/1137: {against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138)}
- C12Y 304/21061: Kexin (3.4.21.61), i.e. proprotein convertase subtilisin/kexin type 9
- C12N 2310/111: spanning the whole gene, or a large part of it
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/314: Phosphoramidates
- C12N 2310/315: Phosphorothioates
- C12N 2310/321: 2'-O-R Modification
- C12N 2310/322: 2'-R Modification
- C12N 2310/3233: Morpholino-type ring
- C12N 2310/332: Abasic residue
- C12N 2310/3515: Lipophilic moiety, e.g. cholesterol
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

The invention relates to sirens targeting a PCs gene, and methods of using sirens to inhibit expression of PCs and to treat PCs related disorders, e.g., hyperlipidemia.

## Claims

### Claim at position 1

-38. (canceled)

### Claim 39

A method for treating hypercholesterolemia in a subject heterozygous for an LDLR gene comprising administering to the subject an effective amount of a dsRNA for inhibiting expression of PCSK9, wherein said dsRNA comprises a sense strand and an antisense strand, the antisense strand comprising a region of complementarity to a PCSK9 RNA transcript and the dsRNA is 30 base pairs or less in length.

### Claim 40 (depends on 39)

The method of claim 39, wherein the dsRNA is lipid formulated.

### Claim 41 (depends on 39)

The method of claim 39, wherein the dsRNA is lipid formulated in a formulation selected from Table A.

### Claim 42 (depends on 39)

The method of claim 39, wherein the subject is a primate or a rodent.

### Claim 43 (depends on 39)

The method of claim 39, wherein the subject is a human.

### Claim 44 (depends on 39)

The method of claim 39, wherein the effective amount is a concentration of 0.01-5.0 mg/kg bodyweight of the subject.

### Claim 45 (depends on 39)

The method of claim 39, further comprising determining an LDLR genotype or phenotype of the subject.

### Claim 46 (depends on 39)

The method of claim 39, wherein administering results in a decrease in serum cholesterol in the subject.

### Claim 47 (depends on 39)

The method of claim 39, further comprising determining the serum cholesterol level in the subject.

### Claim 48 (depends on 39)

The method of claim 39, wherein the region of complementarity consists of one of the antisense sequences of Table 1, 2, 6 or 7.

### Claim 49 (depends on 39)

The method of claim 39, wherein the dsRNA comprises at least one modified nucleotide.

### Claim 50 (depends on 39)

The method of claim 39, wherein the dsRNA comprises at least one 2′-O-methyl modified nucleotide and at least one nucleotide comprising a 5′-phosphorothioate group.

### Claim 51 (depends on 39)

The method of claim 39, wherein the dsRNA comprises at least one modified nucleotide selected from the group consisting of: a 2′-O-methyl modified nucleotide, a 2′-deoxy-2′-fluoro modified nucleotide, a 2′-deoxy-modified nucleotide, a locked nucleotide, an abasic nucleotide, 2′-amino-modified nucleotide, 2′-alkyl-modified nucleotide, morpholino nucleotide, a phosphoramidate, a nucleotide comprising a 5′-phosphorothioate group, and a non-natural base comprising nucleotide.

### Claim 52 (depends on 39)

The method of claim 39, wherein each strand is 19-24 nucleotides in length.

### Claim 53 (depends on 39)

The method of claim 39, wherein each strand comprises a 3′ overhang of 2 nucleotides.

### Claim 54 (depends on 39)

The method of claim 39, wherein the dsRNA further comprises a ligand.

### Claim 55 (depends on 39)

The method of claim 39, wherein the dsRNA further comprises a ligand conjugated to the 3′ end of the sense strand of the dsRNA.
